| Literature DB >> 32964920 |
Javier Santos-Moreno1, Yolanda Schaerli1.
Abstract
Synthetic gene circuits allow us to govern cell behavior in a programmable manner, which is central to almost any application aiming to harness engineered living cells for user-defined tasks. Transcription factors (TFs) constitute the 'classic' tool for synthetic circuit construction but some of their inherent constraints, such as insufficient modularity, orthogonality and programmability, limit progress in such forward-engineering endeavors. Here we review how CRISPR (clustered regularly interspaced short palindromic repeats) technology offers new and powerful possibilities for synthetic circuit design. CRISPR systems offer superior characteristics over TFs in many aspects relevant to a modular, predictable and standardized circuit design. Thus, the choice of CRISPR technology as a framework for synthetic circuit design constitutes a valid alternative to complement or replace TFs in synthetic circuits and promises the realization of more ambitious designs.Entities:
Keywords: CRISPR; gene expression and regulation; synthetic biological circuits; synthetic biology
Mesh:
Substances:
Year: 2020 PMID: 32964920 PMCID: PMC7609024 DOI: 10.1042/BST20200020
Source DB: PubMed Journal: Biochem Soc Trans ISSN: 0300-5127 Impact factor: 5.407
The CRISPR toolbox for gene expression control
| Cas protein | Fusion | Function | Cellular context | Reference(s) |
|---|---|---|---|---|
| dCas9 | - | CRISPRi | [ | |
| dCas9 | RNAP omega subunit | CRISPRa | [ | |
| dCas9 | MS2 aptamer (in gRNA) that recruits MCP-SoxS | CRISPRa | [ | |
| dCas9 | BoxB aptamer (in gRNA) that recruits λN22plus-PspFΔHTH | CRISPRa | [ | |
| dCas9 | AsiA | CRISPRa | [ | |
| dCas9 | KRAB | CRISPRi | Yeast, human cells | [ |
| dCas9 | Mxi1 | CRISPRi | Yeast | [ |
| dCas9 | SRDX | CRISPRi | [ | |
| dCas9 | VP64 | CRISPRa | Yeast, human cells, | [ |
| dCas9 | p65 | CRISPRa | Human cells | [ |
| dCas9 | SunTag-VP64 | CRISPRa | Human cells | [ |
| dCas9 | VPR (VP64-p65-Rta) | CRISPRa | Yeast, fruit fly, mouse and human cells | [ |
| dCas9 | SAM: dCas9-VP64 & MS2 aptamer (in gRNA) that recruits MCP-p65-Hsf1 | CRISPRa | Mouse and human cells | [ |
| dCas9 | TV (tandem TAL and VP64) | CRISPRa | [ | |
| dCas9 | VP64 & MS2 aptamer (in gRNA) that recruits MCP-VP64 | CRISPRa | [ | |
| dCas9 | MS2, PP7 or Com aptamer (in gRNA) that recruits MCP, PCP or Com fused to VP64 or KRAB | CRISPRa/i | Yeast, human cells | [ |
| dCas9 | p300 | Histone acetylation | Human cells | [ |
| dCas9 | HDAC3 | Histone deacetylation | Mouse cells | [ |
| dCas9 | PRDM9 | Histone methylation | Human cells | [ |
| dCas9 | DOT1L | Histone methylation | Human cells | [ |
| dCas9 | LSD1 | Histone demethylation | Mouse cells | [ |
| dCas9 | DNMT3a | DNA methylation | Mouse and human cells | [ |
| dCas9 | TET1 | DNA demethylation | Mouse cells | [ |
| dCas9 | TET1 & MS2 aptamer (in gRNA) that recruits MCP-TET1 | DNA demethylation | Human cells | [ |
| dCas12 | - | CRISPRi | [ | |
| dCas12 | KRAB | CRISPRi | Human cells | [ |
| dCas12 | SRDX | CRISPRi | [ | |
| dCas12 | VP64 | CRISPRa | Human cells | [ |
| dCas12 | p65 | CRISPRa | Human cells | [ |
| dCas12 | VPR (VP64-p65-Rta) | CRISPRa | Human cells | [ |
| Cas13 | - | RNA transcript knockdown | [ |
Figure 1.Gene expression control through CRISPRi and CRISPRa, and strategies to modulate their activity.
(A) Mechanisms of CRISPRi/a-based gene expression control. The activity of ‘helper’ effector domains is required except for bacterial and yeast CRISPRi, where dCas9 alone can efficiently repress gene expression by interfering with transcription initiation or elongation. These effector domains can be either fused to dCas9 or recruited through an additional RNA-recognizing domain that binds to a specific extension of the gRNA. (B) Strategies to modulate CRISPRi/a activity. CRISPR gene control has proved a versatile platform that tolerates numerous engineering extensions. Due to its dual protein-RNA nature, the activity of the dCas9-gRNA complex can be modulated at the level of the protein (dCas9), at the level of the gRNA, or at the interface between the two. Note that for simplicity this panel depicts dCas9 alone, but many of these tuning strategies actually also work with dCas9 fused to effectors.
Figure 2.CRISPR-based synthetic gene circuits.
(A) Examples of CRISPR-based logic gates. Left: AND gate based on ligand-induced heterodimerization domains implemented in human cells [105]. Only in the presence of the two ligands can the activator domain be recruited to the DNA-bound dCas9 and activate GFP expression. Middle: NOR gate constructed in E. coli using gRNAs expressed from inducible promoters [41]. Both gRNAs bind to and repress RFP, and thus only in the absence of both inducers can RFP be expressed. Right: NIMPLY gate in human cells mediated by KRAB-fused dCas9 [142]. YFP expression is enabled when one of the input gRNAs (but not the other) is present. (B) Seven-layer repression cascade built in yeast by using dCas9-Mxi1 [71]. Each new layer inverts the ‘sign’ (i.e. 1 or 0, high or low) of the downstream layers and of the final output. (C) Pulse-generating IFFL in human cells by leveraging dCas9-VPR inactivation by anti-CRISPR proteins [137]. The result is a temporal peak of gene expression. (D) Stripe-forming IFFL in E. coli [69]. In the presence of a gradient of arabinose (Ara, the input inducer), the dCas9-governed circuit forms a peak (stripe) of gene expression at intermediate Ara concentrations. Genetically identical bacteria carrying this circuit form a 3-color pattern in an agar plate when subjected to an Ara gradient. (E) dCas9-controlled toggle switch in E. coli [69]. The circuit can be toggled between the two stable states (green and non-green) through the addition of inducers to the medium: after inducing one of the states, the cells remain in that state even in the absence of any inducer, and the same is true for the opposite state. (F) The CRISPRlator, the first CRISPR oscillator [69]. A dCas9-mediated closed-ring repression topology generates periodic oscillations in E. coli cells.